Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14141 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Yoshiki Katada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Leukopenia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japanese Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Valganciclovir is the first‐line agent for Cytomegalovirus prophylaxis after lung transplantation. However, its use is associated with a relatively high risk of hematological toxicity. This study aimed to investigate the relationship between trough ganciclovir concentration and hematologic toxicity in lung transplantation patients receiving valganciclovir prophylaxis, and identify factors that affect ganciclovir pharmacokinetics in this population.
Methods
This prospective observational study included 24 lung transplant patients receiving valganciclovir prophylaxis. The cutoff value of trough ganciclovir concentration was estimated using receiver operating characteristic analysis in leukopenia grade 3 and higher. Population pharmacokinetic analysis was performed using a nonlinear mixed‐effects modeling program.
Results
The trough ganciclovir concentration was significantly higher in the group with leukopenia grades 3 or higher than in the group with grades less than or equal to 2 (1605.7 ± 860.1 ng/mL [ n = 3] vs. 380.5 ± 175.8 ng/mL ( n = 21), p < .001). The cutoff value of trough ganciclovir concentration for predicting greater than or equal to grade 3 leukopenia was estimated as 872.0 ng/mL. Creatinine clearance and lung re‐transplantation were found to have a significant impact on the total body clearance of valganciclovir. Ganciclovir clearance was decreased in patients with reduced creatine clearance or re‐transplantation.
Conclusion
These results suggest that higher ganciclovir trough concentrations are associated with an increased risk of leukopenia grade 3 or higher, and that creatinine clearance and lung re‐transplantation affected the pharmacokinetics of ganciclovir. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.
- Department of Infection Control and Prevention, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
- Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.
ORCID-Profile: Yoshiki Katada, Keisuke Umemura, Kotaro Itohara
Förderung
- Japanese Society for the Promotion of Science
Zitieren
APA
Katada, Y., Nakagawa, S., Nagao, M., Umemura, K., Itohara, K., Nishikawa, A., Hashi, S., Katsube, Y., Hira, D., Ohsumi, A., Nakajima, D., Date, H., & Terada, T. (2023). Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis. Transplant Infectious Disease. https://doi.org/10.1111/tid.14141
Vancouver
Katada Y, Nakagawa S, Nagao M, Umemura K, Itohara K, Nishikawa A, et al. Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis. Transplant Infectious Disease. 2023. doi:10.1111/tid.14141
BibTeX
@article{Katada2023,
author = {Katada, Yoshiki and Nakagawa, Shunsaku and Nagao, Miki and Umemura, Keisuke and Itohara, Kotaro and Nishikawa, Asami and Hashi, Sachiyo and Katsube, Yurie and Hira, Daiki and Ohsumi, Akihiro and Nakajima, Daisuke and Date, Hiroshi and Terada, Tomohiro},
title = {Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14141}
}
EUVIMED